Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | HTR2B | P41595 | 2/20 | 0.52 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16591260 | 1.00 | KDM1A (0.60) | KDM1ASLC6A3SLC6A2SLC6A4HTR2A | |
| SCHEMBL2615237 | 1.00 | KDM1A (0.60) | KDM1ASLC6A3SLC6A2SLC6A4HTR2A | |
| SCHEMBL26696201 | 1.00 | KDM1A (0.60) | KDM1ASLC6A3SLC6A2SLC6A4HTR2A | |
| SCHEMBL21503486 | 1.00 | KDM1A (0.60) | KDM1ASLC6A3SLC6A2SLC6A4HTR2A | |
| SCHEMBL16234254 | 1.00 | KDM1A (0.60) | KDM1ASLC6A3SLC6A2SLC6A4HTR2A | |
| SCHEMBL12876074 | 1.00 | KDM1A (0.60) | KDM1ASLC6A3SLC6A2SLC6A4HTR2A | |
| SCHEMBL2615236 | 1.00 | KDM1A (0.60) | KDM1ASLC6A3SLC6A2SLC6A4HTR2A | |
| Ammonia Solution, Strong SCHEMBL7928878 | 0.98 | KDM1A (0.58) | KDM1ASLC6A3SLC6A2SLC6A4HTR2A | |
| SCHEMBL13391042 | 0.84 | KDM1A (0.46) | KDM1ASLC6A3SLC6A2SLC6A4HTR2A | |
| SCHEMBL13379965 | 0.84 | KDM1A (0.46) | KDM1ASLC6A3SLC6A2SLC6A4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| EP-3030323-B1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017079753-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS | IMAGO BIOSCIENCES, INC. (US) | 2017-05-11 | — | — | WO | disclosed |
| EP-1541558-B1 | HETEROCYCLIC COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | KDM1A, TET1, KDM3A | KDM1A 1/4885SLC6A3 1552/4885SLC6A2 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.